🟢 90/100

This product looks safe

  • Contains proprietary blend — exact ingredient amounts not disclosed
  • 67% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

ℹ️ Contains proprietary blend — exact ingredient amounts not disclosed

Label Data

1 MicroLingual(R) Tablet(s) Serving Size
100 Servings
Other Combinations Product Type
67% Evidence Coverage

Supplement Facts — Evidence Check

1 mg (5% DV)
✅ Within RDA (0.1× RDA of 14 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 1mg UL 35mg
1000 mcg (16670% DV)
📊 416.7× RDA — above typical dose 📚 138 studies (Tier A: 1, B: 44)
RDA 0.0024mg This product: 1.0mg
Proprietary Blend (Combination)
18 mg

Other Ingredients

Lactose Natural Flavors Acacia

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Directions: As a dietary supplement, dissolve one MicroLingual tablet under the tongue daily. This product may also be swallowed.

Place on or under the tongue

🧪 Formulation Notes

Preservative free

Additional Information

No shot

Our proprietary hydrodrying process results in fewer inactive binders and fillers and a higher ration of nutritional ingredients - hence the small size. They efficiently provide your body with the nutrients you need right now.

Note: Tablet color may vary from light pink to red. Potency is not affected by this natural variance.

"Less is more" Simplicity Purity Efficiency No pills to swallow

Dissolves immediately on contact

Made in USA

Product Details

DSLD Entry Date 2017-02-24
Product Type Other Combinations
Form Tablet or Pill
DSLD ID 70986
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →